# A Study of BND-35 in Participants With Advanced Solid Tumors

> **NCT06274437** · PHASE1 · RECRUITING · sponsor: **Biond Biologics** · enrollment: 280 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** BND-35
- **DRUG:** Nivolumab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT06274437
- **Lead sponsor:** Biond Biologics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-02
- **Primary completion:** 2027-09
- **Final completion:** 2027-11
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06274437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06274437, "A Study of BND-35 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06274437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*